X0508 4 2025-01-03 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001630864 Duker Jay S. C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 true true false false President and CEO false Common Stock 2025-01-05 4 M false 30000.00 0.00 A 68027.00 D Common Stock 2025-01-05 4 F false 10007.00 8.26 D 58020.00 D Common Stock 2025-01-06 4 M false 20794.00 0.00 A 78814.00 D Common Stock 2025-01-06 4 F false 6108.00 8.68 D 72706.00 D Common Stock 22500.00 I By Family Trust Restricted Stock Units 0.00 2025-01-03 4 A false 195000.00 0.00 A Common Stock 195000.00 228334.00 D Stock Option (Right to Buy) 8.26 2025-01-03 4 A false 390000.00 0.00 A 2035-01-03 Common Stock 390000.00 390000.00 D Restricted Stock Units 0.00 2025-01-05 4 M false 30000.00 0.00 D Common Stock 30000.00 60000.00 D Restricted Stock Units 0.00 2025-01-06 4 M false 20794.00 0.00 D Common Stock 20794.00 39206.00 D No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units. These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The restricted stock units will vest in three ratable annual installments beginning January 3, 2026. The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years. The restricted stock units vests in three ratable annual installments beginning January 5, 2025. The restricted stock units vests in three ratable annual installments beginning January 6, 2024. /s/ Ron Honig, Attorney-in-Fact 2025-01-07